Navigation Links
Fulgent Therapeutics Announces Their Comprehensive Hereditary Cancer Test Including BRCA1 and BRCA2 Analysis
Date:6/14/2013

Temple City, CA (PRWEB) June 14, 2013

Fulgent Therapeutics LLC, a CLIA Certified Laboratory, announces the inclusion of BRCA1 and BRCA2 analysis to its Hereditary Cancer Panel. Fulgent Therapeutics is excited to add these key targets, making it the most comprehensive test for cancer risk assessment available.

Fulgent Therapeutics Hereditary Cancer Panel detects mutations in 49 known cancer predisposition genes, now including BRCA1 and BRCA2. “We use well defined processes, robust bioinformatics, and Next Generation Sequencing to provide our clients with a comprehensive look at a true myriad of genes,” according to Dr. Harry Gao, Lab Director for Fulgent Therapeutics.

Personalized medicine demands that we examine diseases in new ways and deploy innovative tools to view all angles of the patient’s health and potential diseases. Fulgent Therapeutics Hereditary Cancer Panel provides patients and physicians with the information to assess their risks and guide their care. “Making molecular diagnostics more comprehensive and at the same time more affordable is our goal,” says Dr. Gao.

Fulgent Therapeutics president, Ming Hsieh stated, “We agree with the Supreme Court’s decision and we look forward to providing physicians with better tools and more options to help their patients."

Fulgent Therapeutics is currently working on panels for more than just cancer. The Next Generation panels for many inherited disease including cardiology, pediatrics, and neurology will provide physicians with more information than previously available.

The release date for the Hereditary Cancer Panel, including BRCA1 and BRCA2, will be available July 8, 2013. Fulgent Therapeutics anticipates that it will provide another first to the industry by getting the 49-gene panel’s price under $3,000.

Additional information: info(at)fulgent-therapeutics(dot)com or 626-350-0537 x106.

About Fulgent Therapeutics LLC: Founded in 2011, Fulgent Therapeutics, LLC is a pharmaceutical and Next Generation molecular diagnostics company focusing on developing and commercializing innovative cancer therapeutics and Next Generation diagnostics. The company has a number of improved generic and innovated drug candidates in its product pipeline for treating a broad range of cancers including those of the breast, lung, ovary, colon, and pancreas. In addition, Fulgent Therapeutics has developed an innovative line of Next Generation diagnostics for both somatic and hereditary diseases.

Fulgent Therapeutics LLC
4978 Santa Anita Ave, Ste 205
Temple City, CA
91780

Read the full story at http://www.prweb.com/releases/2013/6/prweb10833921.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Mainz University obtains new CRC Nanodimensional polymer therapeutics for tumor therapy
2. MDA Awards Valerion Therapeutics $1.2 Million to Continue Myotubular Myopathy Research
3. Corena Therapeutics Launched Coresatin, a Nonsteroidal Cream Used to Treat Critical Skin Conditions and Infections
4. Global Peptide Therapeutics Market - New Market Research Report Published by Transparency Market Research
5. Liver Diseases Therapeutics Market - New Industry Research Report Published by Transparency Market Research
6. Ontario Genomics Institute invests in stem cell technology at Tissue Regenerative Therapeutics
7. Scientist receives $2.8 Million to study cell signaling mechanism and develop potential therapeutics
8. Cancer vaccine Special Focus series published in Human Vaccines & Immunotherapeutics
9. Research shows potential of microneedles to target therapeutics to the back of the eye
10. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
11. FORMA Therapeutics teams with TGen Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... Milford, NJ (PRWEB) , ... October 13, 2017 , ... ... weekend at scenic Alexandria Park in Milford, NJ. This free event, sponsored by ... and physical activity. The fun run is geared towards children of all ages; ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and fastest ... to open a flagship location in Covington, LA at 401 N. U.S. Highway 190, ... next to Office Depot in the Holiday Square shopping center. Its location allows it ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/18/2017)... , Sept. 18, 2017  PMD Healthcare of ... Pharmacy of Kalamazoo, Mich. , have ... service that expedites and streamlines patient and provider access ... 2.0, and wellness management services.  ... used to measure lung function for a variety of ...
Breaking Medicine Technology: